4.5 Article

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation

期刊

BONE MARROW TRANSPLANTATION
卷 47, 期 3, 页码 337-U17

出版社

SPRINGERNATURE
DOI: 10.1038/bmt.2012.5

关键词

hematopoietic cell transplantation; allogeneic; autologous; late complications; screening; prevention

资金

  1. Public Health Service from the National Cancer Institute [U24-CA76518]
  2. National Heart, Lung and Blood Institute [5U01HL069294]
  3. National Institute of Allergy and Infectious Diseases
  4. National Cancer Institute [HHSH234200637015C]
  5. Health Resources and Services Administration (HRSA/DHHS)
  6. Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
  7. AABB
  8. Allos Inc.
  9. Amgen Inc.

向作者/读者索取更多资源

Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (for example, umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, peri-and post-transplant exposures and risk factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplant experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This report provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT. Bone Marrow Transplantation 47; doi:10.1038/bmt.2012.5

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据